An engineered protein antagonist of K-Ras/B-Raf interaction
Abstract Ras is at the hub of signal transduction pathways controlling cell proliferation and survival. Its mutants, present in about 30% of human cancers, are major drivers of oncogenesis and render tumors unresponsive to standard therapies. Here we report the engineering of a protein scaffold for...
Guardado en:
Autores principales: | Monique J. Kauke, Michael W. Traxlmayr, Jillian A. Parker, Jonathan D. Kiefer, Ryan Knihtila, John McGee, Greg Verdine, Carla Mattos, K. Dane Wittrup |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2ce4911947be421fa5711cae0ecd11de |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition
por: Ting Jin, et al.
Publicado: (2017) -
KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation
por: Timothy H. Tran, et al.
Publicado: (2021) -
SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers
por: Greg G. Jones, et al.
Publicado: (2019) -
Sprouty2 regulates positioning of retinal progenitors through suppressing the Ras/Raf/MAPK pathway
por: Jian Sun, et al.
Publicado: (2020) -
Farnesylthiosalicylic Acid-Loaded Albumin Nanoparticle Alleviates Renal Fibrosis by Inhibiting Ras/Raf1/p38 Signaling Pathway
por: Huang H, et al.
Publicado: (2021)